These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 32105293)
21. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856 [TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Kumar D; Unger ER; Panicker G; Medvedev P; Wilson L; Humar A Am J Transplant; 2013 Sep; 13(9):2411-7. PubMed ID: 23837399 [TBL] [Abstract][Full Text] [Related]
23. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ; MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109 [TBL] [Abstract][Full Text] [Related]
24. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663 [TBL] [Abstract][Full Text] [Related]
25. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Jacobson DL; Bousvaros A; Ashworth L; Carey R; Shrier LA; Burchett SK; Renna H; Lu Y Inflamm Bowel Dis; 2013 Jun; 19(7):1441-9. PubMed ID: 23567780 [TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study. Huang Z; He J; Su J; Ou Z; Liu G; Fu R; Shou Q; Zheng M; Group T; Luxembourg A; Liao X; Zhang J Vaccine; 2021 Jan; 39(4):760-766. PubMed ID: 33239228 [TBL] [Abstract][Full Text] [Related]
28. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084 [TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936 [TBL] [Abstract][Full Text] [Related]
30. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial. Lin L; Parra MM; Sierra VY; Cespedes AS; Granados MA; Luque A; Damaso S; Castrejon Alba MM; Romano-Mazzotti L; Struyf F Pediatr Infect Dis J; 2018 Apr; 37(4):e93-e102. PubMed ID: 29424799 [TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885 [TBL] [Abstract][Full Text] [Related]
32. A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol. Zeng Y; Moscicki AB; Sahasrabuddhe VV; Garcia F; Woo H; Hsu CH; Szabo E; Dimond E; Vanzzini S; Mondragon A; Butler V; DeRose H; Chow HS BMC Cancer; 2019 Apr; 19(1):290. PubMed ID: 30935375 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Kojic EM; Kang M; Cespedes MS; Umbleja T; Godfrey C; Allen RT; Firnhaber C; Grinsztejn B; Palefsky JM; Webster-Cyriaque JY; Saah A; Aberg JA; Cu-Uvin S Clin Infect Dis; 2014 Jul; 59(1):127-35. PubMed ID: 24723284 [TBL] [Abstract][Full Text] [Related]
34. A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States. Bruce MG; Meites E; Bulkow L; Panicker G; Hurlburt D; Lecy D; Thompson G; Rudolph K; Unger ER; Hennessy T; Markowitz LE Vaccine; 2020 Sep; 38(42):6585-6591. PubMed ID: 32814639 [TBL] [Abstract][Full Text] [Related]
35. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918 [TBL] [Abstract][Full Text] [Related]
36. Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial. Smahelova J; Hamsikova E; Ludvikova V; Vydrova J; Traboulsi J; Vencalek O; Lukeš P; Tachezy R JAMA Otolaryngol Head Neck Surg; 2022 Jul; 148(7):654-661. PubMed ID: 35653138 [TBL] [Abstract][Full Text] [Related]
37. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status. Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Joshi S; Anantharaman D; Muwonge R; Bhatla N; Panicker G; Butt J; Rani Reddy Poli U; Malvi SG; Esmy PO; Lucas E; Verma Y; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Pillai Rameshwari Ammal Kannan T; Kartha P; Shastri SS; Sauvaget C; Radhakrishna Pillai M; Waterboer T; Müller M; Sehr P; Unger ER; Sankaranarayanan R; Basu P Vaccine; 2023 Jan; 41(1):236-245. PubMed ID: 36446654 [TBL] [Abstract][Full Text] [Related]
39. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572 [TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Wheeler CM; Bautista OM; Tomassini JE; Nelson M; Sattler CA; Barr E; Vaccine; 2008 Jan; 26(5):686-96. PubMed ID: 18164106 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]